USSTOCK.TODAY
Pre-Market
Log in Sign up

Grifols reports 10.3% biopharma revenue growth and net debt ratio below 4.0x in Q3 2026

The Motley Fool +1 · ·by G4L

GRFS
GRFS Grifols SA ADR
$8.76 +0.81%
View chart & analysis →
  1. 1Biopharma segment revenue grew 10.3% on a constant currency basis.
  2. 2Grifols recorded adjusted EBITDA of 538 million euros for the quarter, achieving an adjusted EBITDA margin of 26.4%.
  3. 3The net debt ratio fell below 4.0x.

So what's the key point?

Grifols' biopharma segment revenue grew by 10.3 percent. The net debt ratio was recorded at below 4.0x.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Grifols beats expectations with 2.04 billion euro third-quarter revenue Nasdaq +1 · Nov 3Grifols shares rise 4% as Q3 revenue beats expectations Investing.com +2 · Nov 3Philips (PHG) Q2 comparable sales up 4%, maintains full-year outlook GuruFocus.com +5 · Jul 28
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news